TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics announced that its Phase 2 ZEPHYR trial for ML-007C-MA (schizophrenia treatment) and Phase 2 IRIS trial for ML-004 (autism spectrum disorder) are progressing ahead of schedule, with topline results now expected in Q3 2026. The company cited accelerated enrollment pace and disciplined execution as drivers of the timeline acceleration.

Insights
BACpS   negative

Sold 37 million shares, reducing position by 6%


MPLT   positive

The company reported accelerated enrollment in its Phase 2 trials ahead of schedule, demonstrating strong execution and momentum in clinical development. The narrowed timing guidance to Q3 2026 for both ZEPHYR and IRIS trials indicates progress and operational efficiency, which are positive indicators for investors and stakeholders.